>>155390, >>155391, >>155392, >>155393, >>155394, >>155395, >>155396, >>155397, >>155398, >>155399, >>155400, >>155401, >>155402, >>155403, >>155404, >>155405, >>155406, >>155407, >>155408, >>155409, >>155410, >>155411, >>155412, >>155413, >>155414, >>155415, >>155416, >>155417, >>155418, >>155419, >>155420, >>155421, >>155422, >>155423, >>155424, >>155425, >>155426, >>155427, >>155428, >>155429, >>155430, >>155431, >>155432, >>155433, >>155434, >>155435, >>155436, >>155437, >>155438, >>155439, >>155440, >>155441, >>155442, >>155443, >>155444, >>155445, >>155446, >>155447, >>155448, >>155449, >>155450, >>155451, >>155452, >>155453
10:00 AM EDT
Reassessing Sarbanes-Oxley: The Cost of Compliance in Today’s Capital Markets
House Financial Services Committee
^
WITNESSES:
Dr. Abigail Allen
Associate Professor of Accounting, Marriott School of Business, Brigham Young University
^
Mr. Lawrence Cunningham
Director, Weinberg Center for Corporate Governance, University of Delaware
^
Mr. Frank Watanabe
President and Chief Executive Officer, Arcutis Biotherapeutics
^
Mr. John Coates
Professor of Law and Economics, and Deputy Dean, Harvard Law School